Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References:
Bimeda has announced the launch of a new teat seal which the company claims offers a significant return on investment and an opportunity for veterinary surgeons to prompt farmers to re-evaluate their dry cow therapy and mastitis control.
Bimeda's vet and head of technical services, Padraig Hyland MVB said: "Boviseal is proven to dramatically reduce mastitis in the 100 days post calving¹. Adding competition to the market will encourage farmers to re-assess their dry cow and mastitis strategies.
"The UK launch of Boviseal is a great opportunity for vets to raise the issue of the damage and cost of mastitis, and the potential savings by the correct use of a seal. Boviseal is the number one selling teat seal in the Republic of Ireland, with 2/3 of the Irish dairy cows sealed annually²."
Padraig says the evidence of the value from combined sealing and antibiotic therapy is all too clear when it comes to dry cow therapy. He cites a case study at Waterwheel Farm in Donegal, Ireland which delivered a 300% return on investment: "Combined therapy might sound costly but this two year study saw annual mastitis cases fall dramatically, from 26 per 100 cows to 9 per 100³.
"Defra figures indicate that mastitis is the most costly disease problem that UK dairy farmers face, with a typical case costing £175.00 4. When you compare that against the cost of treatment for the herd, there's no real counter argument in my opinion."
Boviseal contains 65% Bismuth Subnitrate. Padraig says the effectiveness of teat sealing is proven but correct administration is key: "It is important to note that the conventional practice of massaging into the udder after infusion is not employed - the teat seal must stay in the teat canal."
For details on best application practices, the company has developed a website, www.boviseal.co.uk with a video demonstration for correct infusion.
For further information, visit the website or contact Bimeda on 01248 725400.
References
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
Reference
The RSPCA has announced that it will continue its fight to stop the Government's planned cull of badgers after MPs voted against an opposition motion to reverse the Government's strategy aimed at combating bovine TB.
MPs voted 299 to 250 against proposals to stop the cull going ahead in two pilot areas in Somerset and Gloucestershire - a narrower margin than the Government has in the House of Commons despite the three-line whip enforced.
RSPCA chief executive Gavin Grant said: "We fight on. This vote flies in the face of scientific and public opinion. We are grateful to those MPs who spoke out against the cull and particularly those who defied the Government's three line whip.
"There can be little doubt that had MPs been free to express their views through a free vote there would have been a large majority against the cull as there was last October.
"The only real way forward is the vaccination of both cattle and badgers, better biosecurity and control of cattle movements."
The debate follows a report issued by the EFRA select committee which said more investment is urgently needed into vaccination as a solution for bovine TB.
One of the earliest decisions of this government was to cancel five of the six badger vaccination projects planned - a policy the RSPCA believes was short-sighted.
RSPCA chief executive Gavin Grant said: "Much more needs to be done to bring forward the timetable for the development of effective oral vaccination programmes for both cattle and badgers as the EFRA report says.
"Meanwhile we stand ready to work with those who want to vaccinate and save lives rather than cull and kill."
As the open season for shooting badgers begins on 1 June, the British Veterinary Association is reiterating its support for the planned badger cull pilots as part of the overall bovine TB eradication strategy in England.
Although the shooting of badgers is not expected to start until later in the season the BVA says it is responding to activity amongst those who oppose the cull and appealing to them to allow the necessary scientific work to take place unhindered in the two pilot cull areas.
The association points to the evidence base behind the policy - data from the Randomised Badger Culling Trials (RBCTs) - which shows that bovine TB in cattle can be reduced by around 16% in areas where a targeted, humane badger cull has taken place. The pilot culls will use different culling methods to the RBCTs and are therefore being monitored by the Independent Expert Panel made up of experts in veterinary pathology, animal welfare physiology, wildlife ecology, badger behaviour, wildlife management, ecological theory, statistics, and marksmanship.
Peter Jones, President of the BVA, said: "We have not taken the decision to support the pilot badger culls lightly; we have considered all of the scientific evidence, which supports the management of bovine TB in badgers in order to reduce the incidence of the disease in cattle.
"We accept that there is a gap in our knowledge, which is whether controlled shooting can deliver a badger cull humanely and safely, and to the same degree of effectiveness as cage trapping and shooting. That is what the pilots are designed to address and why is it important that they are allowed to go ahead unhindered.
"We understand that this is a highly emotional issue but we must be able to gather the evidence to enable future policy decisions to be based on science."
The Veterinary Medicines Directorate (VMD) has granted MSD Animal Health a provisional UK marketing authorisation for Bovilis SBV, the first vaccine specifically targeting the Schmallenberg virus (SBV) in cattle and sheep.
SBV, which emerged in late 2011, is transmitted via insect vectors, mainly midges and causes transient clinical symptoms in adult cattle and sheep, such as fever, diarrhoea and reduced milk yield, as well as congenital malformation in newborn calves and lambs. As of March 31st 2013, 1753 cases of SBV had been confirmed throughout the UK. SBV has now been detected in every county in England and Wales.
Andras Bolcskei, Country Manager, MSD Animal Health UK said: "On behalf of Merck MSD, we would like to thank the VMD for its partnership and support to fast track the availability of Bovilis SBV to the market. There was a tremendous urgency for a SBV vaccine in the UK especially given the marked increase in confirmed cases over the past year and the increasing importance to help control this devastating disease."
MSD says that studies it conducted in support of the provisional marketing authorisation showed that all animals responded with formation of virus neutralizing antibodies. During the studies, reduced viraemia against SBV was observed in sheep vaccinated once and prevention of viraemia was observed in cattle vaccinated twice, whereas all animals in the control groups developed infection and became viraemic. In studies to date, Bovilis SBV has been shown to be efficacious in cattle and sheep.
The vaccine is based on wild-type SBV that has been inactivated and contains an adjuvant that stimulates the immune response.
The vaccine will be available in 20ml and 100ml vials. Bovilis SBV is indicated for the active immunisation of cattle to prevent viraemia against SBV and for the active immunisation of sheep to reduce viraemia against SBV.
MSD says it is working diligently to expedite stocks to the UK, and expects Bovilis SBV to arrive in the UK in the coming weeks.
BCF has launched a series of instructional videos demonstrating how to perform an ultrasound examination of the bovine reproductive tract, now available online.
The videos were developed by BCF's in-house vet, Kimberly Palgrave, in collaboration with the University of Bristol Veterinary School. They show everything from machine set up and controls, to scanning techniques and features identified in pregnant and non-pregnant cows.
One hour of CPD can be earned by completing a self-assessment quiz after watching the videos.
Kimberly said: "Following the success of the small animal series of instructional videos, we were keen to bring something similar to the bovine market. Our aim for these videos is to give vets a resource to help them either transition from manual palpation to ultrasound or improve their existing ultrasound skills and gain confidence in their technique, as well as being a useful teaching resource for veterinary students. As always, we welcome feedback and suggestions for the future."
To see the videos, visit the farm animal learning section of the BCF website www.bcftechnology.com.
MSD Animal Health has launched a new range of vaccination equipment to help sheep and cattle producers administer its portfolio of farm animal vaccines as effectively, cleanly and safely as possible.
The new vaccinators all incorporate the Sterimatic system, which is designed to take the worry out of administering injections to livestock by delivering an accurate dose of any given product, whilst also cleaning and protecting the needle automatically. MSD says the Sterimatic system also decreases the potential for disease transmission, minimises the risk of infection and abscessing at the vaccination site, and reduces needle-stick injuries.
The new equipment is colour-coded and ergonomically designed for comfort in the hand and comes in clear, sterile bags that list the recommended vaccines for use with each vaccinator.
The new vaccinators are now available from animal health product wholesalers.
To what extent changing diets and adding novel feed additives can cut emissions from beef cattle is being investigated in a new three-year research project.
EBLEX, the organisation for beef and sheep producers in England, has teamed up with Scotland's Rural College, SRUC, in Edinburgh, to look at how changes to feeding regimes can improve efficiency and drive business profitability, while reducing greenhouse gas (GHG) emissions produced as a by-product of rumination.
Steers will be finished on either concentrate based or forage based diets, each with two different feed additives, such as vegetable oils. The role of the rumen microbial population in the responses will be measured to look at how rumen function changes according to diet, additive and breed. Results will be related to the greenhouse gas emissions and feed efficiency, as well as long-term effects of feed additives.
Dr Mary Vickers, senior livestock scientist with EBLEX said: "The animals will be moved into specialist chambers for short periods of time where their emissions can be captured.
"In addition, when they are accessing rations from group pens, special plastic hoods over the feeding stations can measure the specific emissions at those times. Measuring emissions, rumen function, feed intake and growth rates can help us build a picture of any effect the additives have.
"The ultimate aim is to ensure the cattle are having their full nutritional needs met in an efficient, cost effective way while minimising the emissions produced."
In addition, carcase quality, meat quality and shelf life will also be recorded to ensure quality of the final product is maintained. The outcomes of this project will provide producers with independent advice about the efficacy of two feed additives fed in a range of commercial conditions.
Novartis Animal Health has announced the launch of a new campaign called Prepare, Predict, Prevent and designed to raise awareness of blowfly strike management in sheep.
The campaign will include new industry research, an expert-led report, and information tailored to farmers, veterinary surgeons and SQPs. The campaign is aimed at improving awareness of blowfly strike management, with a particular focus on prevention.
In the UK, blowfly strike (myiasis) occurs on over 80 per cent of sheep farms2. If untreated, strike can severely affect the welfare of infested sheep, and may result in death. For farmers, poor management of blowfly strike brings economic costs in terms of the loss of animal, production losses and in terms of treatment and control of the disease, which is easily spread.
Furthermore, previous research from the University of Bristol4, which simulated the pattern of parasite growth in different climate-dependent environments, showed that an increase in average temperature of 3 degrees Celsius would be enough to quadruple the incidence of strike in ewes and double the rate in lambs. This is a growing concern, with climate change models for the UK suggesting that over the next 50 years summer temperatures are set to increase by 1.5 degrees Celsius and winter temperatures by 2.5 degrees Celsius5.
Research conducted at the 2013 Animal Health Distributors Association (AHDA) Annual Conference indicated that, in the past five years, many believe the blowfly strike season is lasting longer and beginning earlier in the year, with the majority of early reported cases occurring unexpectedly in March. The findings have prompted a wider survey from Novartis Animal Health, which is urging SQPs, farmers and key opinion leaders nationwide to contribute answers at: www.farmanimalhealth.co.uk/fleecebind-questionnaire.
Katherine Openshaw, Ectoparasiticides Category Manager at Novartis Animal Health, said: "This has always been a serious issue for the sheep industry and elevated temperature is likely to bring about increased levels of blowfly strike and a longer season.
"We recognise the need to evolve attitudes towards parasite control and to provide farmers and prescribers with the knowledge and tools needed to facilitate a better management of blowfly strike. The 'Prepare, Predict, Prevent' campaign is all about simple, yet effective, measures to prevent the occurrence of blowfly strike, which can be enough to ensure farmers are protected from the potentially devastating impacts of flock infestation, offering season peace of mind.
"We have developed a range of materials to aid prescribers in promoting preventative solutions to farmers; these include farmer leaflets, posters and counter displays. We will also be offering training support so prescribers are best equipped to help farmers make informed decisions about preventative blowfly solutions."
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.
Loseley, the ice-cream maker, has announced that it has developed a new way of making flavoured ice-cream by adapting the diet fed to its cows.
The first variety to be made using the new technique is 'Eton Mess', for which the company's herd is being fed a diet of strawberries and meringues.
Loseley says its cattle - which are housed at the Beechdean Dairies farm in Buckinghamshire - have already been feeding on the ingredients found in the much loved pudding for over a year, to ensure their milk supply is infused with the strawberry and meringue flavours. Apparently, huge amounts of strawberries are having to be air-freighted into the UK in order to ensure an uninterrupted supply through the seasons.Andrew Howard Managing Director of Beechdean Dairies said: "We have been perfecting the quantities in the cattle feed for over 18 months to perfect the Eton Mess flavour. The cows need to be fed just the right quantities of meringues, strawberries, fat and hay to make the perfect Eton Mess ice cream. We believe ice cream should be great quality, tasty and interesting. Our products will always deliver against these criteria."Vince Bamford, Fast Moving Consumer Goods Editor at The Grocer, the UK's leading grocery trade magazine said: "Loseley's flavour development process is cutting edge - I have tasted the product and it is delicious. It is an exciting innovation for the ice cream category."
Norbrook Laboratories Ltd has launched a second generation Eprinomectin Pour On solution with zero milk withhold and a 10 day meat withdrawal period. Eprizero, for beef and dairy cattle, is indicated for the treatment and prevention of a range of economically damaging gutworm and lungworm infections and external parasites in a pour on application. It offers zero milk withhold and an improved meat withdrawal period of 10 days. Andrew Hillan MVB MRCVS, Director of Veterinary Science, Norbrook Laboratories Ltd., said: "Norbrook has launched Eprizero to offer vets and farmers a more versatile alternative in the treatment of economically damaging worms and external parasites. The active ingredient in Eprizero, Eprinomectin, is both potent and fast-acting and is supported by independent studies which show increased milk yield, improved fertility and increased dry matter intake following treatment. With a zero milk and 10 day meat withdrawal and waterproof properties, Eprizero offers real versatility to vets and farmers in terms of when and where they treat. It is this versatility that we believe will make Eprizero the gold standard in anthelmintic treatment for prolonged infestations of gut worm and lung worm in both dairy and beef cattle." Eprizero is available in four sizes - 250ml, 1L, 2.5L and 5L - with a free 75ml gun supplied with the two larger pack sizes. It is administered using a 75ml dispensing gun to enable accurate application. Eprizero is registered for use in the UK and Ireland and is available to order from your local Norbrook Sales Representative.
New research published in Epidemiology and Infection (Cambridge University Press) reveals that direct contact between badgers and cattle is rare, suggesting that it may be rare for bovine tuberculosis (TB) to be passed on through the two species meeting each other on pasture.
For the research, which was conducted by the Royal Veterinary College and the Food and Environment Research Agency, researchers investigated direct and indirect interactions between badgers and cattle by fitting automated high-tech proximity loggers to animals and placing base stations at badger latrines located on pasture, in an area of south-west England with a high-density badger population, over a period of 12-months.
Direct interactions (within 1.4 metres) between badgers and cows at pasture were very rare, with only four out of over 500,000 animal-to-animal contacts recorded between the two species.
Indirect interactions (visits to badger latrines) were far more frequent than direct contacts, with 400 visits by badgers and 1700 visits by cattle recorded. This suggests that indirect contacts might be more important than direct in terms of disease transmission at pasture.
During the study half of the badgers tested positive for TB, however the infection status of individual badgers did not affect the frequency or duration of their visits to latrines located on pasture grazed by cattle.
Bovine tuberculosis caused by infection with Mycobacterium bovis is endemic in cattle in parts of England and Wales and its control is hindered by the presence of infection in the European badger. While M. bovis is clearly transmitted between cattle and badgers, it is has not previously been known where, when or how often transmission occurs.
Dr Julian Drewe from the Royal Veterinary College who led the study, said: "Our findings reveal that direct contacts between badgers and cattle at pasture are surprisingly rare, despite ample opportunity for interactions to occur, suggesting that the two species may be ignoring or even actively avoiding one another. The study was conducted in an area with a high badger population, so it is likely that such direct contact will be even less frequent in areas of the country where there are fewer badgers.
"Indirect visits by both species to badger latrines were significantly more common than direct contacts between badgers and cattle, which suggests that these represent the more typical nature of interspecies contact. Future research aiming to quantify TB risk to cattle from badgers might be best to focus on indirect contacts occurring at latrines and on contacts occurring away from pasture, for example in farm buildings.
"This clearly has disease management implications, and more work is now needed in this area to look at how such contact can be limited, to reduce the number of cases of bovine TB in the future."
Elanco Animal Health has announced the launch of Kexxtone this month, a new treatment which it claims can reduce the incidence of ketosis in dairy cows by 74%* following a single treatment.1
Kexxtone is a targeted solution for any dairy cow or heifer that is expected to develop ketosis around the period of calving. It is administered as a bolus,and provides coverage during the main risk period for the condition.
Ketosis often goes undetected because the signs are not immediately apparent. However, it is a common condition, affecting around 30% of cows2 and has a negative impact upon cow health, fertility and milk production. Ketosis can result, on average, in milk losses of around 350-500 litres per cow4 per lactation. The cost of production losses and disease related consequential losses due to subclinical ketosis has been estimated at around 250-600 EUR per cow.5
Elanco says this new approach is likely to significantly expand the array of options open to vets actively involved in dairy herd health management. Kexxtone comes with the benefit of a zero day milk and meat withdrawal3 and the formulation is based on monensin - a molecule with a long history of beneficial use.
According to the company, Kexxtone uses novel technology to allow a continuous and regular release of the active ingredient into the rumen which forms a gel when exposed to rumen fluid. This gel is progressively released into the rumen by a pressure sensitive spring in the Kexxtone device. The active ingredient shifts the microbial balance in the rumen to produce more of the glucose precursor propionic acid, therefore increasing glucose delivery and ultimately increasing the energy available to the cow. This improvement in energy utilisation buffers dairy cows against the tendency to drop into negative energy balance during the transition period around calving and early lactation - the major cause of ketosis.
Mike Steele, Technical Consultant at Elanco said: "Kexxtone offers an exciting opportunity in which everyone wins - vets who can offer positive interventions able to make a big impact on the bottom line, are going to be increasingly integral to their farm clients' herd health planning framework. It's no longer just about nutritional intervention and emergency salvage; it's about being able to proactively easily measure the true herd prevalence of ketosis and where appropriate, take preventative targeted action to really make a difference."
Kexxtone is available to order now from veterinary wholesalers - for further information contact the Elanco Territory Manager or call Elanco Animal Health on 01256 353131.
Dairy nutrition consultant Hefin Richards of Profeed Nutrition Consultancy is warning vets to be on the lookout for an upsurge in over-conditioned cows as winter progresses through spring.
He says his prediction is based on a number of factors that have come together over the last year to greatly increased the risk of cows being over-conditioned at calving, not only potentially affecting productivity but predisposing to a number of clinical conditions.
A high body condition score at calving significantly increases the risk of subclinical ketosis in early lactation, depressing the immune response and increasing the risk of conditions such as retained foetal membranes, metritis and left displaced abomasum.1,2 Conversely, these obese cows go on to suffer excessive body condition loss due to decreased voluntary feed intake and poor energy metabolism.
The ketosis risk has been increased in part because national milk yields were low last summer and autumn as a result of poor weather conditions, low milk prices, high feed costs and the spread of Schmallenberg virus (SBV).3
Hefin said: "SBV and bad summer weather with associated poor forage quality may have delayed rebreeding, leading to more extended lactations and longer dry periods. These two factors can lead to excessively fat cows at calving."
Through the winter many herds were running average milk yields some way below usual winter levels and currently mid and late lactation cows are substantially under target yields.4 This lower yield means that feed intake is very likely to be in excess of actual energy demands, with subsequent fat deposition.
Increasing awareness of this potential issue gives vets the opportunity to reinforce the need to monitor body condition, adjust feeding, review milk yields and consider drying cows off early, using controlled energy feeding.
Hefin suggests that vets ensure that their clients' dry cow nutrition and management is geared towards maximising feed intake in early lactation to help prevent animals falling into a state of negative energy balance. Ketosis is often missed on farm because the signs are not apparent. Consider routinely monitoring herds for ketosis using either blood monitoring or Elanco's Keto-Test cow-side milk test to identify both at-risk cows and herds. Forming a team involving vets, nutritionists and herd managers and harnessing the different skill sets and knowledge allows strategies to be developed that can improve herd performance.
The RCVS Disciplinary Committee has reprimanded a veterinary surgeon for submitting a certificate of Clinical Inspection for Veterinary Inspectors ("TB52") for tuberculin tests he had undertaken on cattle, despite knowing that he had not fully complied with the standard operating procedures (SOP) for these tests.
At the outset of the three-day hearing, John Wilson admitted that, when acting as an Official Veterinarian (OV) he had not carried out tuberculin tests on cattle at a Wiltshire farm on 19 May 2011 strictly in accordance with the SOP required by the Animal Health and Veterinary Laboratories Agency (AHVLA), an executive agency of Defra.
The admitted shortcomings were that on 19 May, the second day of testing, Mr Wilson had failed to confirm the identity of all the animals, failed to inspect the animals digitally (ie using his hands) and had not measured the fold of skin at the injection site of all the animals. The College argued that this was contrary to the directions of the AHVLA and, in subsequently signing the TB52 certificate, he was either dishonest or should have known that the certification was incorrect. Mr Wilson admitted that he ought to have known the certification was incorrect but denied dishonesty, because he believed that he had conducted the test in a satisfactory manner and had correctly identified all the reactors in the herd.
Mr Wilson was a veterinary surgeon of over 40 years experience and unblemished record, and the Committee found his account of events to be accurate and honest. He said the farm involved was unprepared and test arrangements were chaotic, with poor handling facilities, and he would have been concerned for the safety of the animals and their handlers if he had complied fully with the SOP. He had advised the farmer to delay the test but his advice was rejected.
The Committee accepted that the testing had been carried out under exceptional and difficult circumstances. It noted that Mr Wilson had identified a reactor and taken appropriate actions, knowing that the outcome would be the quarantining of the whole herd. He had made no financial or other gain, other than the nominal fee charged for the work. Although failing to comply with the SOP fell short of what was expected of a veterinary surgeon, because of these circumstances, and as he had acted in what he considered to be the best interests of the animals and personnel, these actions did not amount to serious professional misconduct.
The Committee found that, even allowing for these difficulties and concerns, in signing the TB52 certificate a few days later, without any qualification, Mr Wilson ought to have known that it was incorrect, and his actions fell far short of the standards expected of the veterinary profession. They did not however find that he had been dishonest.
The Committee stressed the importance attached to accurate and reliable certification, in maintaining the confidence of the public and the profession, and in ensuring animal welfare.
Professor Lees, chairing and speaking on behalf of the committee said: "The Committee is aware, as confirmed by AHVLA, that this is a single, isolated event and the first offence in some 40 years of the Respondent working as a LVI [local veterinary inspector] or OV. After considering all the mitigating factors.and, given the exceptional circumstances of this specific case, the decision of the Committee is to reprimand Mr Wilson."
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).
Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.
"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.
"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.
"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."
Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.
"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.
"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."
Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
Welsh Environment Minister, John Griffiths, has announced changes to some bovine TB cattle and surveillance controls to provide a higher level of protection against the disease.
The Minister confirmed that from 1 April 2013, some existing Pre Movement Testing exemptions will be amended. The main changes concern movements from markets and common land.
New key measures are:
The Minister announced that a new dedicated TB epidemiologist was to be appointed for Wales and that he or she would work within the AHVLA and focus on specific areas or clusters of disease. The postholder will be in place by April 2013.
He also announced new advice and support to farms dealing with breakdowns: "I have also asked officials to develop a way to provide additional advice and support to farmers to clear up breakdowns more quickly and efficiently. We have started to explore how private vets could become more involved with this new initiative called the Integrated Breakdown Management Project.
"I know that bovine TB is a devastating disease that has a big impact in rural communities. Since I launched the Strategic Framework for Bovine TB Eradication last March, we have kept the programme under constant review. With the new tools I have outlined today, we are addressing TB in livestock and wildlife and maintaining an effective eradication programme for the benefit of farmers, rural communities and the economy in general."
Elanco Animal Health is reminding vets about the importance of correctly interpreting oocyst counts in the diagnosis of coccidiosis during the post lambing period.
The company says scouring lambs that are failing to thrive should immediately ring the alarm bells for coccidiosis. Typically, oocyst counts of >20,000 per gram are cited as diagnostic for coccidiosis in sheep, but counts of up to 100,000 oocysts per gram have been reported in apparently healthy lambs and disease can also occur in the presence of low or negligible counts where there is gut damage but before oocysts have been shed.1 These discrepancies can lead to misdiagnosis and as such, oocyst counts should always be interpreted with care.
Oocysts of the fourteen Eimeria species described as specific to sheep are indistinguishable from each other by eye and only two species - E. ovinoidalis and E. crandallis, are actually pathogenic.1 For this reason, diagnosing coccidiosis based on clinical signs of diarrhoea and oocysts in their faeces alone can generate false positives. This could lead to important differentials, such as Nematodirus battus infection (for lambs at pasture) being left untreated.
According to the company, false negatives are also a concern, particularly as prompt treatment of clinical cases with an anti-coccidial, such as diclazuril (Vexocan® 2.5mg/ml oral suspension) has been proven to reduce the convalescence period.2 Shedding of oocysts varies with disease progression and faecal counts can fluctuate significantly.3 For example, a delay between the development of clinical signs and oocysts appearing in faeces is common. Another possibility is sub-clinical disease, with affected lambs showing no typical outward signs. The gut damage caused by the parasite can be significant in these animals though, adversely affecting growth rates.
Elanco says that for reliable diagnosis of coccidiosis, faecal oocyst counts should be considered alongside disease and farm history, followed with Eimeria species identification if possible. The disease typically affects groups of lambs aged between 3-8 weeks old and is often triggered by a stressor such as castration, weaning, turnout and/or bad weather. If clinical signs appear around three weeks after such an event, the suspicion of coccidiosis can be heightened. For some farms, predictable stressors cause disease outbreaks year after year and in these cases, a metaphylactic dose of Vecoxan® can be administered to susceptible lambs 14 days after the trigger event.
Finally, the company says veterinary surgeons should also not forget the importance of good management when advising farmers about coccidiosis control. Lambing pen and high traffic area hygiene and age batching lambs are essential for long term control.